{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:39:43Z","timestamp":1790894383484,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp;amp; Rheumatology"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the prognostic utility of circulating interleukin\u201018 (IL\u201018) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in patients with Still disease (SD) receiving first\u2010line IL\u20101 inhibitors (IL\u20101i).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 66 biologic\u2010naive patients with SD who received first\u2010line treatment with IL\u20101i. Plasma IL\u201018 levels were measured at baseline and at 3, 6, and 12 months after IL\u20101i initiation. Associations between IL\u201018 levels and clinical outcomes were assessed using mixed\u2010effects models, receiver operating characteristic (ROC) curve analysis, and multivariate logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median baseline IL\u201018 levels were 61,425 pg\/mL (interquartile range 16,194\u2013235,746) and declined significantly after IL\u20101 blockade (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Higher IL\u201018 levels persisted in patients with active disease (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Baseline IL\u201018 &gt;45,000 pg\/mL predicted active disease at 12 months (area under the curve [AUC] 0.82;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.0002), MAS development within 24 months (AUC 0.78;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.01), and a chronic\u2013persistent course (AUC 0.73;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.007). In multivariate models, elevated baseline IL\u201018 and delayed IL\u20101i initiation for more than three months independently predicted adverse outcomes. Strikingly, at three months, IL\u201018 &gt;15,000 pg\/mL was a stronger predictor of chronic\u2013persistent course (AUC 0.92;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), independent of clinical disease activity (odds ratio 25.6;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.01), with the multivariate model explaining 67% of variance (AUC 0.95).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In biologic\u2010naive patients with SD, IL\u201018 levels, especially reassessed three months after IL\u20101i initiation, robustly predict long\u2010term disease activity, MAS risk, and chronic\u2013persistent trajectory. Early measurement and dynamic monitoring of IL\u201018 may enable risk stratification and guide timely therapeutic escalation or treatment adjustment to improve outcomes.<\/jats:p>\n                    <jats:p>\n                      <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                        <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/art70024-gra-0001-m.png\">\n                          <jats:alt-text>image<\/jats:alt-text>\n                        <\/jats:graphic>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.70024","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T06:01:06Z","timestamp":1765864866000},"page":"1327-1338","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Interleukin\u201018 Levels Are Associated With Disease Course in Patients With Still Disease Treated With Interleukin\u20101 Inhibitors"],"prefix":"10.1002","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1897-7701","authenticated-orcid":false,"given":"Matteo","family":"Trevisan","sequence":"first","affiliation":[{"name":"Department of Rheumatology IRCCS Ospedale Pediatrico Bambino Ges\u00f9  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0850-7351","authenticated-orcid":false,"given":"Manuela","family":"Pardeo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology IRCCS Ospedale Pediatrico Bambino Ges\u00f9  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Caiello","sequence":"additional","affiliation":[{"name":"Laboratory of Immuno\u2010Rheumatology IRCCS Ospedale Pediatrico Bambino Ges\u00f9  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9834-9619","authenticated-orcid":false,"given":"Claudia","family":"Bracaglia","sequence":"additional","affiliation":[{"name":"Department of Rheumatology IRCCS Ospedale Pediatrico Bambino Ges\u00f9  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-4407","authenticated-orcid":false,"given":"Arianna","family":"De Matteis","sequence":"additional","affiliation":[{"name":"Department of Rheumatology IRCCS Ospedale Pediatrico Bambino Ges\u00f9  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Matteo","sequence":"additional","affiliation":[{"name":"Laboratory of Immuno\u2010Rheumatology IRCCS Ospedale Pediatrico Bambino Ges\u00f9  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Loricchio","sequence":"additional","affiliation":[{"name":"Laboratory of Immuno\u2010Rheumatology IRCCS Ospedale Pediatrico Bambino Ges\u00f9  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8749-8232","authenticated-orcid":false,"given":"Fabrizio","family":"De Benedetti","sequence":"additional","affiliation":[{"name":"Department of Rheumatology IRCCS Ospedale Pediatrico Bambino Ges\u00f9  Rome Italy"},{"name":"Laboratory of Immuno\u2010Rheumatology IRCCS Ospedale Pediatrico Bambino Ges\u00f9  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusi","family":"Prencipe","sequence":"additional","affiliation":[{"name":"Laboratory of Immuno\u2010Rheumatology IRCCS Ospedale Pediatrico Bambino Ges\u00f9  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225851"},{"issue":"2","key":"e_1_2_7_3_1","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty RE","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050473"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.25.022106.141627"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2023.06.007"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38615"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2018.02.002"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000634"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2012.11.025"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez282"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.06.005"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq133"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu524"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-9-15"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab113"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.43217"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38296"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa634"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21774"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200011)43:11<2402:AID-ANR5>3.0.CO;2-C"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-023-00886-9"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225854"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1218312"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180168"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20497"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roae036"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39332"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141567"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41612"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40865"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30128"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180331"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23437"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004317"},{"issue":"6","key":"e_1_2_7_36_1","first-page":"653","article-title":"Interleukin 6: a possible marker of disease activity in adult onset Still's disease","volume":"14","author":"Scheinberg MA","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120079"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae440"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01353-y"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212608"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.70024","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.70024","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.70024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:19:05Z","timestamp":1783930745000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.70024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/art.70024"],"URL":"https:\/\/doi.org\/10.1002\/art.70024","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"2025-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}